- Home
- HG vs NAMS Comparison
HG vs NAMS Comparison
Compare HG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- NAMS
- Stock Information
- Founded
- HG 2013
- NAMS 2019
- Country
- HG Bermuda
- NAMS Netherlands
- Employees
- HG N/A
- NAMS N/A
- Industry
- HG
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- HG
- NAMS Health Care
- Exchange
- HG Nasdaq
- NAMS Nasdaq
- Market Cap
- HG 1.9B
- NAMS 1.9B
- IPO Year
- HG 2023
- NAMS N/A
- Fundamental
- Price
- HG $19.06
- NAMS $19.98
- Analyst Decision
- HG Buy
- NAMS Strong Buy
- Analyst Count
- HG 8
- NAMS 6
- Target Price
- HG $21.50
- NAMS $33.80
- AVG Volume (30 Days)
- HG 416.4K
- NAMS 738.7K
- Earning Date
- HG 11-06-2024
- NAMS 11-06-2024
- Dividend Yield
- HG N/A
- NAMS N/A
- EPS Growth
- HG 537.51
- NAMS N/A
- EPS
- HG 4.48
- NAMS N/A
- Revenue
- HG $2,266,708,000.00
- NAMS $33,594,000.00
- Revenue This Year
- HG N/A
- NAMS $134.88
- Revenue Next Year
- HG $7.19
- NAMS N/A
- P/E Ratio
- HG $4.25
- NAMS N/A
- Revenue Growth
- HG 68.94
- NAMS 78.77
- 52 Week Low
- HG $12.44
- NAMS $8.90
- 52 Week High
- HG $20.71
- NAMS $26.35
- Technical
- Relative Strength Index (RSI)
- HG 59.89
- NAMS 44.67
- Support Level
- HG $18.83
- NAMS $19.21
- Resistance Level
- HG $19.29
- NAMS $21.66
- Average True Range (ATR)
- HG 0.38
- NAMS 1.22
- MACD
- HG 0.08
- NAMS -0.50
- Stochastic Oscillator
- HG 78.92
- NAMS 12.60
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in Lloyd's, Ireland, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.